^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DetermaIO™

    Company:
    Oncocyte
    Type:
    Laboratory Developed Test
    Related tests:
    DetermaIO is a novel gene expression assay that measures expression levels of 27-genes to assess various components of the tumor immune microenvironment (TIME). The test has been shown to identify patients that are likely to benefit from immune checkpoint inhibitor (ICI) therapy.​
    Cancer:
    Non Small Cell Lung Cancer
    Gene:
    Other genes, PD-L1 (Programmed death ligand 1)
    Method:
    PCR
    Confirmatory trial(s)
    NeoTRIPaPDL1
    ,
    NCT02620280
    |
    ESMO 2021